The PPP2R4 antibody targets the regulatory subunit B56δ (encoded by the PPP2R4 gene) of protein phosphatase 2A (PP2A), a critical serine/threonine phosphatase involved in diverse cellular processes. PP2A holoenzymes consist of a structural (A), catalytic (C), and variable regulatory (B) subunit. The B56 family, including B56δ, determines substrate specificity and subcellular localization, modulating PP2A's role in cell cycle regulation, apoptosis, signal transduction (e.g., Wnt, MAPK, PI3K/Akt pathways), and tumor suppression. Dysregulation of PPP2R4/B56δ is linked to cancer, neurodegenerative disorders, and cardiovascular diseases, underscoring its importance in maintaining cellular homeostasis.
The PPP2R4 antibody is widely used in research to investigate PP2A complex dynamics, protein expression, and post-translational modifications. Applications include Western blotting, immunofluorescence, immunohistochemistry, and co-immunoprecipitation to study B56δ interactions and localization. Commercial antibodies are typically raised in rabbits or mice, with specificity validated across human, mouse, and rat samples. Studies employing PPP2R4 antibodies have elucidated its tumor-suppressive roles via dephosphorylation of oncogenic kinases and its involvement in stress responses. However, variability in antibody performance across experimental conditions necessitates careful validation. This tool remains vital for dissecting PP2A-mediated regulatory mechanisms in health and disease.